Testing a new prostate cancer screening approach in men aged 50 to 63
Tests a prostate cancer screening method in men aged 50 to 63 in Finland.
Plain-language title generated from the registry record
Registry title: A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
Key facts
- Where
- Helsinki and Tampere, FinlandSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 63 years old?
Source: NCT03423303, who can take part
Where in Finland
- Helsinki University and Helsinki University HospitalHelsinki, FinlandNo longer taking part
- University of TampereTampere, FinlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tampere University
- Trial code
- NCT03423303
- Record updated
- 17 April 2025
- Original description
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm. A reduction in harms of screening in the form of overdiagnosis is sought, while retaining as much as possible of the mortality benefit (reduction in prostate cancer mortality). Novel methods that have been shown to increase specificity for clinically relevant prostate cancer but never tested in a randomised setting will be employed in screening and diagnostics. The main end-point is prostate cancer mortality at 10 and 15 years of follow-up.Read full original descriptionShow less
Randomized Population-Based Pragmatic Prostate Cancer Screening Trial Based on PSA, Kallikrein Panel, and MRI
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm. A reduction in harms of screening in the form of overdiagnosis is sought, while retaining as much as possible of the mortality benefit (reduction in prostate cancer mortality). Novel methods that have been shown to increase specificity for clinically relevant prostate cancer but never tested in a randomised setting will be employed in screening and diagnostics. The main end-point is prostate cancer mortality at 10 and 15 years of follow-up.
Inclusion: 50-63-year-old men (age in 2018) residing in Tampere or Helsinki.
Exclusion: Prevalent prostate cancer.